Background: The new anti-cancer drug imatinib mesylate inhibits the tyrosine kinase growth factor receptor, c-KIT, and has shown spectacular activity in patients with gastrointestinal stromal tumours (GISTs).

背景： 的新的抗癌药物伊马替尼甲磺酸抑制酪氨酸激酶生长因子受体，C-KIT，并在胃肠道间质肿瘤 (GISTS) 表现出特别的效果。

Objective: To assess whether fluorodeoxyglucose positron emission tomography (FDG PET) is suitable for response evaluation of this new type of tumour treatment.

目的： 评估脱氧正电子发射断层扫描 (FDG PET) 适合反应评价这种新型肿瘤的治疗方法。

Methods: Sixteen consecutive patients with irresectable or metastasized GIST or another c-KIT (CD117) positive mesenchymal tumour underwent FDG PET before and 1 week after the start of treatment with imatinib mesylate (Glivec^®). Visual findings and standard uptake values (SUVs) were compared with the overall response to treatment, based on clinical and radiological response.

方法： 16 例胃肠道间质瘤或一个 c-KIT(CD117) 积极间质肿瘤用FDG PET,在开始甲磺酸伊马替尼 （格列卫 ®） 的治疗的1 周前。视觉的调查结果和根据临床及影像学为标准摄取值 (suvs)的整体反应进行了比较。